A basal stem cell signature identifies aggressive prostate cancer phenotypes.

Evidence from numerous cancers suggests that increased aggressiveness is accompanied by up-regulation of signaling pathways and acquisition of properties common to stem cells. It is unclear if different subtypes of late-stage cancer vary in stemness properties and whether or not these subtypes are transcriptionally similar to normal tissue stem cells.

We report a gene signature specific for human prostate basal cells that is differentially enriched in various phenotypes of late-stage metastatic prostate cancer. We FACS-purified and transcriptionally profiled basal and luminal epithelial populations from the benign and cancerous regions of primary human prostates. High-throughput RNA sequencing showed the basal population to be defined by genes associated with stem cell signaling programs and invasiveness. Application of a 91-gene basal signature to gene expression datasets from patients with organ-confined or hormone-refractory metastatic prostate cancer revealed that metastatic small cell neuroendocrine carcinoma was molecularly more stem-like than either metastatic adenocarcinoma or organ-confined adenocarcinoma. Bioinformatic analysis of the basal cell and two human small cell gene signatures identified a set of E2F target genes common between prostate small cell neuroendocrine carcinoma and primary prostate basal cells. Taken together, our data suggest that aggressive prostate cancer shares a conserved transcriptional program with normal adult prostate basal stem cells.

Proceedings of the National Academy of Sciences of the United States of America. 2015 Oct 12 [Epub ahead of print]

Bryan A Smith, Artem Sokolov, Vladislav Uzunangelov, Robert Baertsch, Yulia Newton, Kiley Graim, Colleen Mathis, Donghui Cheng, Joshua M Stuart, Owen N Witte

Department of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, CA 90095;, Center for Biomolecular Science and Engineering, University of California, Santa Cruz, CA 95064;, Department of Biomolecular Engineering, University of California, Santa Cruz, CA 95064;, Center for Biomolecular Science and Engineering, University of California, Santa Cruz, CA 95064;, Department of Biomolecular Engineering, University of California, Santa Cruz, CA 95064;, Department of Biomolecular Engineering, University of California, Santa Cruz, CA 95064;, Department of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, CA 90095;, Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, CA 90095;, Center for Biomolecular Science and Engineering, University of California, Santa Cruz, CA 95064; Department of Biomolecular Engineering, University of California, Santa Cruz, CA 95064; Department of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, CA 90095; Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, CA 90095; Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA 90095; Howard Hughes Medical Institute, University of California, Los Angeles, CA 90095 

PubMed

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe